{
    "ticker": "MTEM",
    "name": "Molecular Templates, Inc.",
    "description": "Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for oncology. Founded in 2013 and headquartered in Austin, Texas, the company is pioneering a unique platform known as its Engineered Toxin Bodies (ETB) technology. This proprietary platform enables the creation of potent and selective therapeutics designed to target and eliminate cancer cells while sparing healthy tissue. Molecular Templates aims to develop its lead product candidate, MT-3724, which is designed to treat patients with relapsed or refractory non-Hodgkin lymphoma. In addition to MT-3724, the company is advancing a diverse pipeline of product candidates that leverage its ETB technology, including collaborations with major pharmaceutical companies to enhance therapeutic efficacy in various cancer types. Molecular Templates is dedicated to addressing unmet medical needs in oncology and improving patient outcomes through its innovative therapeutic approaches. The company is committed to rigorous scientific research and clinical trials to validate the effectiveness and safety of its therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2013",
    "website": "https://www.moleculartemplates.com",
    "ceo": "Eric P. R. T. L. O'Connor",
    "social_media": {
        "twitter": "https://twitter.com/MolecularTempl1",
        "linkedin": "https://www.linkedin.com/company/molecular-templates/"
    },
    "investor_relations": "https://investors.moleculartemplates.com",
    "key_executives": [
        {
            "name": "Eric P. R. T. L. O'Connor",
            "position": "CEO"
        },
        {
            "name": "Mark D. C. R. S. S. F. A. R. B. B. A. K. A. G. W. A. J. T. T. M. A. R. M. W. K. R.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "MT-3724"
            ]
        }
    ],
    "seo": {
        "meta_title": "Molecular Templates, Inc. | Innovative Oncology Therapeutics",
        "meta_description": "Explore Molecular Templates, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment using its proprietary Engineered Toxin Bodies technology.",
        "keywords": [
            "Molecular Templates",
            "Biotechnology",
            "Cancer Therapeutics",
            "MT-3724",
            "Oncology",
            "ETB Technology"
        ]
    },
    "faq": [
        {
            "question": "What is Molecular Templates known for?",
            "answer": "Molecular Templates is known for its innovative Engineered Toxin Bodies technology and development of oncology therapeutics."
        },
        {
            "question": "Who is the CEO of Molecular Templates?",
            "answer": "Eric P. R. T. L. O'Connor is the CEO of Molecular Templates, Inc."
        },
        {
            "question": "Where is Molecular Templates headquartered?",
            "answer": "Molecular Templates is headquartered in Austin, Texas, USA."
        },
        {
            "question": "What is the lead product candidate of Molecular Templates?",
            "answer": "The lead product candidate of Molecular Templates is MT-3724, aimed at treating non-Hodgkin lymphoma."
        },
        {
            "question": "When was Molecular Templates founded?",
            "answer": "Molecular Templates was founded in 2013."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "MRNA",
        "NVAX",
        "BNTX",
        "CRSP"
    ]
}